{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:20:02Z","timestamp":1795029602055,"version":"4.10.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sarcopenia has been associated with conventional chemotherapy-related toxicity, postoperative complications and poor overall survival in patients with genotype-unselected metastatic colorectal cancer (mCRC). This study aimed to evaluate the prognostic implications of sarcopenia and its change after perioperative cetuximab plus doublet chemotherapy and hepatectomy in patients with RAS wild-type colorectal liver metastasis (CRLM). Patients with CRLM from 2007 to 2018 in Chang Gung Research Database were retrospectively analyzed. Baseline characteristics as well as skeletal muscle index (SMI) at baseline and dynamic changes after interventions were collected. A multivariate Cox proportional hazard model was used to evaluate the effect of each parameter on overall survival (OS), and the Kaplan\u2013Meier method was used to establish survival curves. A two-sided p value\u2009&lt;\u20090.05 was considered statistically significance. Of 214 RAS wild-type mCRC patients who received both cetuximab and doublet chemotherapy, 77 who received upfront or subsequent hepatectomy were included in this study. The median follow-up time was 2.3\u00a0years. The rate of sarcopenia was higher in the patients who received neoadjuvant cetuximab-containing regimens than in those who received upfront hepatectomy (95% versus 63%, p\u2009=\u20090.001). Increased SMI after perioperative systemic therapy remained independently associated with better OS in multivariate analysis [hazard ratio (HR)\u2009=\u20090.27\/10% increase, p\u2009=\u20090.013). The patients with sarcopenia had a trend of worse OS than those without sarcopenia (median OS: 4.5 versus 3.6\u00a0years, log-rank p\u2009=\u20090.282). Improvement in sarcopenia ([SMI after intervention \u2212 initial SMI]\/initial SMI\u2009\u00d7\u2009100%) is an important prognostic factor for OS. Future research is warranted to investigate direct interventions for sarcopenia and the impact on OS.<\/jats:p>","DOI":"10.1038\/s41598-023-33439-x","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:02:42Z","timestamp":1682600562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy"],"prefix":"10.1038","volume":"13","author":[{"given":"Yao-Ren","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Sheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Che","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"33439_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers13092025","volume":"13","author":"Sawicki","year":"2021","unstructured":"Sawicki, et al. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel) 13, 9 (2021).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"33439_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"33439_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm9123889","volume":"9","author":"J Aparicio","year":"2020","unstructured":"Aparicio, J. et al. Metastatic colorectal cancer. First line therapy for unresectable disease. J. Clin. Med. 9, 12 (2020).","journal-title":"J. Clin. Med."},{"issue":"2","key":"33439_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand, C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 22(2), 229\u2013237 (2004).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"33439_CR5","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.18.02258","volume":"37","author":"HJ Lenz","year":"2019","unstructured":"Lenz, H. J. et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB\/SWOG 80405 (alliance). J. Clin. Oncol. 37(22), 1876\u20131885 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"33439_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal, A. et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10\u201330 (2005).","journal-title":"CA Cancer J. Clin."},{"issue":"22","key":"33439_CR7","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz, S. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27(22), 3677\u20133683 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"33439_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"33439_CR9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011\u20132019 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"33439_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.12998\/wjcc.v8.i7.1188","volume":"8","author":"O Vergara-Fernandez","year":"2020","unstructured":"Vergara-Fernandez, O., Trejo-Avila, M. & Salgado-Nesme, N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J. Clin. Cases 8(7), 1188\u20131202 (2020).","journal-title":"World J. Clin. Cases"},{"issue":"1","key":"33439_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jcsm.12234","volume":"9","author":"MH Choi","year":"2018","unstructured":"Choi, M. H. et al. Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer. J. Cachexia Sarcopenia Muscle 9(1), 53\u201359 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"5","key":"33439_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/DCR.0000000000001352","volume":"62","author":"JJ Hopkins","year":"2019","unstructured":"Hopkins, J. J. et al. The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer. Dis. Colon Rectum 62(5), 549\u2013560 (2019).","journal-title":"Dis. Colon Rectum"},{"key":"33439_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clnesp.2019.04.004","volume":"32","author":"LP da Cunha","year":"2019","unstructured":"da Cunha, L. P. et al. Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation. Clin. Nutr. ESPEN 32, 107\u2013112 (2019).","journal-title":"Clin. Nutr. ESPEN"},{"issue":"6","key":"33439_CR14","doi-asserted-by":"publisher","first-page":"e0218761","DOI":"10.1371\/journal.pone.0218761","volume":"14","author":"PG Vashi","year":"2019","unstructured":"Vashi, P. G. et al. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. PLoS\u00a0One 14(6), e0218761 (2019).","journal-title":"PLoS\u00a0One"},{"issue":"12","key":"33439_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen, S. et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J. Clin. Oncol. 34(12), 1339\u20131344 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"33439_CR16","doi-asserted-by":"publisher","first-page":"O256","DOI":"10.1111\/codi.13067","volume":"17","author":"DD Huang","year":"2015","unstructured":"Huang, D. D. et al. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis. 17(11), O256\u2013O264 (2015).","journal-title":"Colorectal Dis."},{"issue":"7","key":"33439_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1477-2574.2011.00301.x","volume":"13","author":"PD Peng","year":"2011","unstructured":"Peng, P. D. et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 13(7), 439\u2013446 (2011).","journal-title":"HPB (Oxford)"},{"issue":"2","key":"33439_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00595-017-1564-0","volume":"48","author":"R Nakanishi","year":"2018","unstructured":"Nakanishi, R. et al. Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surg. Today 48(2), 151\u2013157 (2018).","journal-title":"Surg. Today"},{"issue":"6","key":"33439_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/bjc.2012.350","volume":"107","author":"JR Lieffers","year":"2012","unstructured":"Lieffers, J. R. et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br. J. Cancer 107(6), 931\u2013936 (2012).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"33439_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret, M. et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr. Cancer 66(4), 583\u2013589 (2014).","journal-title":"Nutr. Cancer"},{"issue":"3","key":"33439_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"H-W Jung","year":"2015","unstructured":"Jung, H.-W. et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support. Care Cancer 23(3), 687\u2013694 (2015).","journal-title":"Support. Care Cancer"},{"issue":"1","key":"33439_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.hpb.2021.08.947","volume":"24","author":"RB Waalboer","year":"2022","unstructured":"Waalboer, R. B. et al. Sarcopenia and long-term survival outcomes after local therapy for colorectal liver metastasis: A meta-analysis. HPB (Oxford) 24(1), 9\u201316 (2022).","journal-title":"HPB (Oxford)"},{"issue":"5","key":"33439_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bj.2017.08.002","volume":"40","author":"MS Tsai","year":"2017","unstructured":"Tsai, M. S. et al. Chang Gung Research Database: A multi-institutional database consisting of original medical records. Biomed. J. 40(5), 263\u2013269 (2017).","journal-title":"Biomed. J."},{"issue":"7","key":"33439_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9(7), 629\u2013635 (2008).","journal-title":"Lancet Oncol."},{"issue":"2","key":"33439_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","volume":"29","author":"M Muscaritoli","year":"2010","unstructured":"Muscaritoli, M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d. Clin. Nutr. 29(2), 154\u2013159 (2010).","journal-title":"Clin. Nutr."},{"issue":"4","key":"33439_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","volume":"12","author":"RA Fielding","year":"2011","unstructured":"Fielding, R. A. et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. J. Am. Med. Dir. Assoc. 12(4), 249\u2013256 (2011).","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"6","key":"33439_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jamda.2011.04.014","volume":"12","author":"JE Morley","year":"2011","unstructured":"Morley, J. E. et al. Sarcopenia with limited mobility: An international consensus. J. Am. Med. Dir. Assoc. 12(6), 403\u2013409 (2011).","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"1","key":"33439_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft, A. J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 48(1), 16\u201331 (2019).","journal-title":"Age Ageing"},{"issue":"8","key":"33439_CR29","doi-asserted-by":"publisher","first-page":"767.e1","DOI":"10.1016\/j.jamda.2016.05.016","volume":"17","author":"LK Chen","year":"2016","unstructured":"Chen, L. K. et al. Recent advances in sarcopenia research in Asia: 2016 update from the Asian Working Group for sarcopenia. J. Am. Med. Dir. Assoc. 17(8), 767.e1\u20137 (2016).","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"5","key":"33439_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis, M. et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997\u20131006 (2008).","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"33439_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cells11152313","volume":"11","author":"L Goodla","year":"2022","unstructured":"Goodla, L. & Xue, X. The role of inflammatory mediators in colorectal cancer hepatic metastasis. Cells 11, 15 (2022).","journal-title":"Cells"},{"issue":"5","key":"33439_CR32","doi-asserted-by":"publisher","first-page":"M326","DOI":"10.1093\/gerona\/57.5.M326","volume":"57","author":"M Visser","year":"2002","unstructured":"Visser, M. et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J. Gerontol. A Biol. Sci. Med. Sci. 57(5), M326\u2013M332 (2002).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"3","key":"33439_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejso.2021.09.010","volume":"48","author":"T Bajri\u0107","year":"2022","unstructured":"Bajri\u0107, T. et al. Sarcopenia and primary tumor location influence patients outcome after liver resection for colorectal liver metastases. Eur. J. Surg. Oncol. 48(3), 615\u2013620 (2022).","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33439-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:03:08Z","timestamp":1682600588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33439"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33439-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2358572\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"8 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6911"}}